L106
Loxapine succinate salt
solid
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C18H18ClN3O · C4H6O4
化学文摘社编号:
分子量:
445.90
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
248-682-0
MDL number:
Form:
solid
Quality level:
form
solid
Quality Level
color
white
solubility
H2O: soluble
originator
Watson
SMILES string
CN(CC1)CCN1C2=NC3=C(C=CC=C3)OC4=C2C=C(Cl)C=C4.OC(CCC(O)=O)=O
InChI
1S/C18H18ClN3O.C4H6O4/c1-21-8-10-22(11-9-21)18-14-12-13(19)6-7-16(14)23-17-5-3-2-4-15(17)20-18;5-3(6)1-2-4(7)8/h2-7,12H,8-11H2,1H3;1-2H2,(H,5,6)(H,7,8)
InChI key
YQZBAXDVDZTKEQ-UHFFFAOYSA-N
Gene Information
human ... DRD2(1813), DRD3(1814), DRD4(1815), HTR2A(3356), HTR2B(3357), HTR2C(3358), HTR7(3363)
Biochem/physiol Actions
D2/D4 dopamine receptor antagonist; 5-HT2A/2B, 5-H7 serotonin receptor antagonist; dibenzoxazepine antipsychotic agent.
Features and Benefits
This compound was developed by Watson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
法规信息
新产品
此项目有
H O Kalkman et al.
British journal of pharmacology, 124(7), 1550-1556 (1998-09-02)
1. The mechanism underlying the anticataleptic properties of the atypical neuroleptic agent, clozapine, has been investigated in the rat. 2.The close structural analogues of clozapine, loxapine (0.1 mg kg(-1) s.c.) and iso-clozapine (1 and 3 mg kg(-1) s.c.) induced catalepsy
Andrea Reed et al.
Drug metabolism letters, 6(1), 26-32 (2012-02-04)
The antipsychotic drugs risperidone, paliperidone, olanzapine, quetiapine, aripiprazole, clozapine, haloperidol, and chlorpromazine have been reported to have various degrees of interaction (substrate or inhibitor) with the multidrug resistance transporter, P-glycoprotein (P-gp). An interaction of the antipsychotic drug loxapine with P-gp
Tamara Pringsheim et al.
Canadian journal of psychiatry. Revue canadienne de psychiatrie, 56(10), 630-634 (2011-10-22)
To describe the frequency and trends in the use of antipsychotics for adults with schizophrenia in Canada from 2005 to 2009. Analyses were performed on IMS Brogan's Canadian Disease and Therapeutic Index (CDTI). The CDTI is a national physician panel
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| L106-100MG | 04061832091679 |
| L106-500MG | 04061833949214 |